Global study probes patient views on gene therapy for hemophilia b
NCT ID NCT05044845
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study interviewed 150 people with hemophilia B, their caregivers, and healthcare workers from around the world to learn what they know and how they feel about gene therapy. The goal is to create better educational materials and improve the consent process, especially in countries with limited resources. No treatment was given—only interviews were conducted.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENE THERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Civil Service Hospital
Kathmandu, Nepal
-
Hospital Dos De Mayo
Lima, Peru
-
National Hospital of Sri Lanka
Colombo, 01000, Sri Lanka
-
National Institute of Hematology and Blood Transfusion
Hanoi, Vietnam
-
Ramathibodi Hospital
Bangkok, 10400, Thailand
-
St. Jude Children's Research Hospital
Memphis, Tennessee, 38105, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A Once-a-Week shot could transform hemophilia Care—Even for those with inhibitors
- Gene Editing's lasting impact: a 10-Year safety watch
- Can a single gene shot free hemophilia b patients from regular infusions?
- Can a video call replace the clinic for hemophilia pain relief?
- Newborn screening study aims to catch rare diseases at birth
- Monthly shot could free kids with hemophilia from frequent infusions